Ovarian Cancer News and Research RSS Feed - Ovarian Cancer News and Research Twitter

Commonly known as the "silent killer," ovarian cancer leads to approximately 15,000 deaths each year in the United States, according to the American Cancer Society. Approximately 20,000 new cases are diagnosed each year, with the majority in patients diagnosed with late stage disease where the cancer has spread beyond the ovary. The prognosis is poor in these patients, leading to the high mortality from this disease. A diagnostic test is needed that can provide adequate predictive value to stratify patients with a pelvic mass into high risk of invasive ovarian cancer versus those with low risk, as well as a screening test for the diagnosis of early-stage ovarian cancer, which is essential for improving overall survival in patients. Ovarian cancer has up to a 90% cure rate following surgery and/or chemotherapy if detected in stage 1.
Early epigenetic changes could open way for new preventative strategies for ovarian cancer

Early epigenetic changes could open way for new preventative strategies for ovarian cancer

Research revealing early changes at epigenetic level points to possible new prevention strategies for ovarian cancer. The discovery of early changes in the cells of the Fallopian tubes of women carrying the BRCA genetic mutation could open the way for new preventative strategies for ovarian cancer, reducing the need for invasive surgery, according to research published today in science journal Nature Communications. [More]
BUSM researchers uncover genetic, epigenetic alteration overlaps in breast and ovarian cancer

BUSM researchers uncover genetic, epigenetic alteration overlaps in breast and ovarian cancer

While breast cancer is the most common cause of cancer death in women worldwide, ovarian cancer also is a significant source of mortality as the fifth leading cause of cancer death among women. [More]
New spectral triangulation system may help pinpoint targeted cancer tumors

New spectral triangulation system may help pinpoint targeted cancer tumors

Bathing a patient in LED light may someday offer a new way to locate tumors, according to Rice University researchers. [More]
Combination of chemotherapy and immunotherapy may be effective against ovarian cancer

Combination of chemotherapy and immunotherapy may be effective against ovarian cancer

Inside each ovarian tumor, there are good cells and bad cells: The bad cells are fibroblasts. They work to block chemotherapy, which is why nearly every woman with ovarian cancer becomes resistant to treatment. [More]
AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca and its global biologics research and development arm, MedImmune, will provide an update on their extensive oncology pipeline at the annual meeting of the American Society of Clinical Oncology in Chicago, USA, on 3-7 June 2016. [More]
Study assesses utility of tumor cfDNA as predictor of therapeutic response to immunotherapy

Study assesses utility of tumor cfDNA as predictor of therapeutic response to immunotherapy

Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, today announces positive data from a blinded proof of concept clinical study, assessing the utility of tumor cell-free DNA as a predictor of therapeutic response to immunotherapy after the first cycle of treatment in eight different types of cancer. [More]
MGH researchers develop device to rapidly diagnose health-care-associated infections

MGH researchers develop device to rapidly diagnose health-care-associated infections

A team of Massachusetts General Hospital investigators has developed a device with the potential of shortening the time required to rapidly diagnose pathogens responsible for health-care-associated infections from a couple of days to a matter of hours. [More]
Importance of understanding ovarian cancer on molecular level

Importance of understanding ovarian cancer on molecular level

Nearly 70 percent of ovarian cancer cases are detected after metastasis, which is the development of secondary malignant growths distant from the primary site of cancer. [More]
Implication of microRNAs in cancer development greater than previously thought

Implication of microRNAs in cancer development greater than previously thought

Small, non-coding molecules called microRNAs are known to play an important role in cancer development. Researchers now have shown their significance is greater than previously thought, a finding that could lead to new therapeutic approaches for the most common and deadly form of ovarian cancer. [More]
Expanding gene panel beyond known breast/ovarian cancer genes does not add any clinical benefit

Expanding gene panel beyond known breast/ovarian cancer genes does not add any clinical benefit

Running large, multi-gene sequencing panels to assess cancer risk is a growing trend in medicine as the price of the technology declines and more precise approaches to cancer care gain steam. The tests are particularly common among breast and ovarian cancer patients. However, questions remain about the growing list of mutations and their suspected, but unproven association with breast and ovarian cancer risk. [More]
Rare germ cell tumor creates unique bond between two young women

Rare germ cell tumor creates unique bond between two young women

Morgan Ellison and Madison McDaniel were diagnosed with a rare germ cell tumor of the ovary earlier this year. The two strangers would soon form a unique bond during their treatment in Birmingham, Alabama. [More]
Excess abdominal fat in obese African American women could hide symptoms of ovarian cancer

Excess abdominal fat in obese African American women could hide symptoms of ovarian cancer

African American women with ovarian cancer are more likely to die from the disease than are White women and they are also much more likely to be obese. These factors may be linked by the new finding that excess abdominal fat in overweight and obese women could interfere with the detection of early symptoms of ovarian cancer, as presented in a study published in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Women's Health website until May 28, 2016. [More]
New gene testing method can identify mutations, prioritize variants in breast and ovarian cancer genes

New gene testing method can identify mutations, prioritize variants in breast and ovarian cancer genes

A research team led by an award-winning genomicist at Western University has developed a new method for identifying mutations and prioritizing variants in breast and ovarian cancer genes, which will not only reduce the number of possible variants for doctors to investigate, but also increase the number of patients that are properly diagnosed. [More]
New class of cancer-driver gene may serve as unique therapeutic targets, biomarkers in TNBC

New class of cancer-driver gene may serve as unique therapeutic targets, biomarkers in TNBC

The discovery of long non-coding RNA (lncRNA) has dramatically changed the understanding of the biology of diseases such as cancer. The human genome contains about 20,000 protein-coding genes - less than 2 percent of the total - but 70 percent of the genome is made into non-gene-encoding RNA. [More]
Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

Ludwig Cancer Research and the Cancer Research Institute have launched a Phase 1/2 clinical trial of combination immunotherapy for advanced ovarian cancer. The international, multicenter trial is led by George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne and Brad Monk, director of Gynecologic Oncology at St. Joseph's Hospital and Medical Center. [More]
Study may help identify unborn children at higher risk for birth defects

Study may help identify unborn children at higher risk for birth defects

Researchers at the University of Toronto have discovered a novel function performed by the breast cancer 1 protein (BRCA1), which regulates DNA repair. Well known for the role it plays in breast and ovarian cancer, this study revealed that the BRCA1 protein actually plays a much broader biological role, particularly in protecting the developing embryo from the damaging effects of reactive oxygen species (ROS). [More]
Kevin Rudi Superhero 5K Fun Run to raise money for sarcoma research

Kevin Rudi Superhero 5K Fun Run to raise money for sarcoma research

The second annual Kevin Rudi Superhero 5K Fun Run will start and end by the Memorial Stadium Field House in Las Cruces. Money raised for sarcoma research will benefit The University of New Mexico Comprehensive Cancer Center. [More]
SGO acting on ovarian cancer report recommendations

SGO acting on ovarian cancer report recommendations

During the Society of Gynecologic Oncology’s 47th Annual Meeting on Women’s Cancer today, SGO convened a panel of ovarian cancer experts to discuss the recently released report by the National Academy of Medicine (NAM), [More]
Genetic testing in women with ovarian cancer helps determine prognosis

Genetic testing in women with ovarian cancer helps determine prognosis

A study examining mutations in DNA repair genes in women with advanced ovarian cancer found that the disease remained at bay longer in women with the mutations than without, and that women having cancers with these mutations lived longer. [More]
Targeted therapies suppress T cell activity that could actually help fight tumors

Targeted therapies suppress T cell activity that could actually help fight tumors

In many cases, targeted therapies for cancer are preferred as treatments over chemotherapy and surgery because they attack and kill cancer cells with specific tumor-promoting mutations while sparing healthy, normal cells that do not express these mutations. [More]
Advertisement